“Impact of CardiolRx on Myocardial Recovery in patients with Acute Myocarditis. A double-blind, placebo-controlled trial (ARCHER)”
The ARCHER study is looking into a new medicine, CardiolRx, for people who have acute myocarditis. This condition means the heart muscle has become inflamed, often after an infection. In this study, some participants will receive CardiolRx, while others will get a placebo (a dummy medicine with no active ingredients). This is to fairly compare if CardiolRx helps the heart recover more effectively. We will be checking how well the heart's tissues are healing and how well the heart muscle is working after 12 weeks of treatment using special scans. Our aim is to find out if CardiolRx can make a real difference in helping people with acute myocarditis get better.
At a glance
What is this study about?
Acute myocarditis is a condition where your heart muscle becomes inflamed. This can happen for various reasons, often after a viral infection. When your heart muscle is inflamed, it can sometimes struggle to pump blood effectively, leading to symptoms like chest pain, shortness of breath, and tiredness. For some people, this inflammation can cause lasting damage, so finding ways to help the heart recover is really important.
The ARCHER study is investigating a new medicine called CardiolRx. We want to see if this medicine can help repair the heart muscle more effectively in people who have acute myocarditis. To do this fairly, we'll compare CardiolRx against a placebo. A placebo looks just like the real medicine but contains no active ingredients. This helps us know if any improvements seen are truly due to CardiolRx and not just other factors. Crucially, neither you nor your study doctor will know if you're receiving CardiolRx or the placebo until after the study is over. This is called a 'double-blind' study and helps ensure the results are unbiased.
We will be looking at specific changes in your heart using special heart scans, called Cardiac Magnetic Resonance (CMR) scans, 12 weeks after you start the treatment. These scans can measure subtle changes in the heart's tissue and how well the heart muscle is contracting. By comparing these measurements between the group who received CardiolRx and the group who received the placebo, we hope to understand if CardiolRx makes a significant difference in helping your heart recover.
Key takeaways
- This study tests a new medicine, CardiolRx, for acute myocarditis.
- It aims to see if CardiolRx helps the heart heal better.
- Some people will get CardiolRx, others a dummy medicine (placebo).
- Special heart scans will measure heart recovery after 12 weeks.
- Participation involves regular visits and tests.
- Your decision to join is voluntary, and you can withdraw anytime.
Who may be eligible?
To join this study, you must be at least 18 years old. There's no upper age limit, meaning people of any age over 18 can be considered.
Both men and women are welcome to take part in the study. The researchers want to include a wide range of people to make sure the results apply to many different patients.
Other specific medical details will be checked by the study team to make sure it's safe and appropriate for you to participate, as not everyone with acute myocarditis will be suitable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years of age or older?
- Have you been diagnosed with acute myocarditis?
- Are you able to attend regular appointments for about 12 weeks?
- Are you comfortable with having medical tests including heart scans and blood tests?
What does participation involve?
If you decide to take part in the ARCHER study, you would first have health checks to confirm you're eligible. Once you're enrolled, you would receive either the study medicine (CardiolRx) or a placebo, which you would take as instructed. Neither you nor your doctor will know which one you are receiving during the study.
You would need to attend several appointments over approximately 12 weeks. These visits will involve various assessments, including physical examinations, blood tests, and special heart scans called Cardiac Magnetic Resonance (CMR) scans, which help us see how your heart is working and healing. These scans are important for measuring the main effects of the medicine.
After the initial 12 weeks of treatment and assessments, there might be further follow-up appointments to check on your long-term health. The exact number of visits and tests will be explained in detail by the study team, and you'll have plenty of opportunities to ask questions.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is acute myocarditis?
Acute myocarditis is when the heart muscle becomes inflamed, often due to an infection like a virus. This can make the heart struggle to pump properly.
What is CardiolRx?
CardiolRx is the name of the new medicine being tested in this study. We want to see if it helps the heart heal better from acute myocarditis.
What is a 'placebo'?
A placebo is a dummy medicine that looks like the real drug but has no active ingredients. It helps us fairly compare if the real medicine is actually working.
What is a 'double-blind' study?
Double-blind means neither you nor your doctor will know if you're getting the active medicine or the placebo. This helps make the study results more reliable.
How long will I be in the study?
The main part of the study, including treatment and key assessments, lasts about 12 weeks. There may also be follow-up appointments after this.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.